-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/appendix-d-surveillance-report-1.xlsx
September 30, 2015 - Appendix Table D-1. RCTs
Table D-1. Randomized controlled trials
Author, Year Study design
Duration Setting
Country Eligibility criteria Interventions Sample Characteristics Screened
Eligible
Randomized
Analyzed Results Adverse Events and Withdrawals Due To Adverse Events Sponsor Quality
Hruschak, 2021 RCT
Duration:…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-d-opioid-chronic-pain-surveill-report-1.xlsx
September 30, 2015 - Appendix Table D-1. RCTs
Table D-1. Randomized controlled trials
Author, Year Study Design
Duration Setting
Country Eligibility Criteria Interventions Sample Characteristics Screened
Eligible
Randomized
Analyzed Results Adverse Events and Withdrawals Due to Adverse Events Sponsor Quality
Hruschak, 2021 RCT
Duration:…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cancer-anemia-update_executive.pdf
April 01, 2013 - 1
Epoetin and Darbepoetin for Managing
Anemia in Patients Undergoing Cancer
Treatment: Comparative Effectiveness Update
Executive Summary
Background
Anemia, a deficiency in the concentration
of hemoglobin-containing red blood
cells, is prevalent among cancer patients,
depending on the type of malignancy
and t…
-
effectivehealthcare.ahrq.gov/sites/default/files/glaucoma_screening-apendices-11-5-10.pdf
December 23, 2009 - Appendix A2: FDA status of medical devices for glaucoma screening
APPENDIX A FDA STATUS- SCREENING DEVICES
SE: Substantially equivalent; Premarket notification, 501(k)
Page 1 of 19
Ophthalmoscope, AC-powered
Product code: HLI
COMPANY PRODUCT FDA STATUS* APPROVAL DATE
ACCUTECH MEDICAL TECHNOLOGIES IN…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/glaucoma-screening-apendices-11-5-10.pdf
December 23, 2009 - Appendix A2: FDA status of medical devices for glaucoma screening
APPENDIX A FDA STATUS- SCREENING DEVICES
SE: Substantially equivalent; Premarket notification, 501(k)
Page 1 of 19
Ophthalmoscope, AC-powered
Product code: HLI
COMPANY PRODUCT FDA STATUS* APPROVAL DATE
ACCUTECH MEDICAL TECHNOLOGIES IN…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-d-opioid-chronic-pain-surveillance-report-3.xlsx
September 30, 2015 - Appendix Table D-1. RCTs
Table D-1. Randomized controlled trials
Author, Year Study Design
Duration Setting
Country Eligibility Criteria Interventions Sample Characteristics Screened
Eligible
Randomized
Analyzed Results Adverse Events and Withdrawals Due to Adverse Events Sponsor Quality
Hruschak, 2021 RCT
Duration:…
-
effectivehealthcare.ahrq.gov/sites/default/files/estimation-and-reporting_chapter-3.pptx
January 01, 2013 - analysis)
To predict whether an individual might benefit from a treatment (predictive learning)
Goals for Analyzing … Heterogeneity of
Treatment Effect
Goals for Analyzing Heterogeneity of Treatment Effect
Analyses
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-e-surveillance-report-1-treatments-for-acute-pain.xlsx
December 22, 2021 - E-1. KQ1 RCTs
Table E-1. Key Question 1: Acute back pain treatment trials
Author, Year
(Appendix C has full citations of included studies) Setting Country
Specific Pain Condition Radiculopathy Intervention Types Compared Intervention Names and Doses Intervention Dose in Daily Morphine Equivalent N Randomized N Anal…
-
effectivehealthcare.ahrq.gov/products/observational-studies/white-paper
December 13, 2013 - Observational Studies: Empirical Evidence of Their Contributions to Comparative Effectiveness Reviews
White Paper December 13, 2013 Web Version [NLM Site] Download Main Document PDF 263.9 KB
People using assistive technology may not be able to fully access information in these files. For additional assi…
-
effectivehealthcare.ahrq.gov/products/dementia-agitation-aggression/research
March 21, 2016 - Current Page Topic Timeline Mar. 7, 2013 Topic Suggestion Nov. 13, 2014 Research Protocol Mar. 21, 2016 Systematic Review Nonpharmacologic Interventions for Agitation and Aggression in Dementia
Systematic Review Archived March 21, 2016 Web Version [NLM Site] Download Main Document PDF 6.3 MB
Related …
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-d-surv-report-2-noninvasive-nonpharma_0.xlsx
January 01, 2022 - Title
Appendix D. Evidence Table
Table D-1. Evidence Table
Table D-1. Evidence table for new trials included in surveillance reports for noninvasive nonpharmacological treatment for chronic pain report
Author, Year
Country
Number of Centers and Setting Inclusion/Exclusion Criteria Number …
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-d-surv-report-3-noninvasive-nonpharma_0.xlsx
January 01, 2022 - Title
Appendix D. Evidence Table
Table D-1. Evidence Table
Table D-1. Evidence table for new trials included in surveillance reports for noninvasive nonpharmacological treatment for chronic pain report
Author, Year
Country
Number of Centers and Setting Inclusion/Exclusion Criteria Number …
-
effectivehealthcare.ahrq.gov/products/mental-health-apps/topic-overview
March 01, 2021 - Current Page Topic Timeline Mar. 1, 2021 Topic Initiated Mar. 1, 2021 Topic Overview Evaluation of Mental Health Applications
Overview March 1, 2021
Americans suffering from behavioral health conditions, especially mild behavioral or chronic medical conditions, may not seek or receive care due to st…
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-results-search-strategies-developed-with-without-text-mining-tools.pdf
March 01, 2021 - set and comparator set,
development of the search strategy with references from the development set (analyzing
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-d-surveillance-report-1-noninvasive-nonpharm-chronic-pain.xlsx
January 01, 2021 - Title
Appendix D. Evidence Tables
Table D-1. Evidence Tables
Table D-1. Evidence tables for new trials included in surveillance report 1 for noninvasive nonpharmacological treatment for chronic pain report
Author, Year
Country
Number of centers and setting Inclusion/Exclusion Criteria Num…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-d-surv-report-1-noninvasive-nonpharma.xlsx
January 01, 2021 - Title
Appendix D. Evidence Table
Table D-1. Evidence Table
Table D-1. Evidence table for new trials included in Surveillance Report 1 for noninvasive nonpharmacological treatment for chronic pain report
Author, Year
Country
Number of Centers and Setting Inclusion/Exclusion Criteria Number…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-d-surv-report-1-noninvasive-nonpharma_0.xlsx
January 01, 2021 - Title
Appendix D. Evidence Table
Table D-1. Evidence Table
Table D-1. Evidence table for new trials included in Surveillance Report 1 for noninvasive nonpharmacological treatment for chronic pain report
Author, Year
Country
Number of Centers and Setting Inclusion/Exclusion Criteria Number…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-d-surv-report-2-noninvasive-nonpharma.xlsx
January 01, 2021 - Title
Appendix D. Evidence Table
Table D-1. Evidence Table
Table D-1. Evidence table for new trials included in Surveillance Report 1 for noninvasive nonpharmacological treatment for chronic pain report
Author, Year
Country
Number of Centers and Setting Inclusion/Exclusion Criteria Number…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/appendix-g-surveillance-report-1.xlsx
November 22, 2021 - RCTs
Author, year Randomization adequate Allocation concealment adequate Patients and personnel masked Outcome assessors masked Groups similar at baseline Intent-to-treat analysis (at least 95% analyzed) Attrition < 20%; Difference between groups <10% Avoidance of selective outcomes reporting Quality rating
Chakrabar…
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/app-g-surv-report-1-nonopioid-pharmacol-chronic-pain.xlsx
September 20, 2022 - RCTs
Table G-1. Quality assessments of included randomized controlled trials
Author, Year Randomization Adequate Allocation Concealment Adequate Patients and Personnel Masked Outcome Assessors Masked Groups Similar at Baseline Intent-to-Treat Analysis (at Least 95% Analyzed) Attrition <20%; Difference Between Groups …